LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

Search

AbCellera Biologics Inc

Cerrado

SectorSalud

2.44 2.52

Resumen

Variación precio

24h

Actual

Mínimo

2.4

Máximo

2.45

Métricas clave

By Trading Economics

Ingresos

17M

-34M

Ventas

-1.5M

5.1M

BPA

-0.12

Margen de beneficio

-677.426

Empleados

596

EBITDA

-3.4M

-55M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+387.39% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

54M

757M

Apertura anterior

-0.08

Cierre anterior

2.44

Noticias sobre sentimiento de mercado

By Acuity

61%

39%

336 / 387 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 mar 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Global Business Travel Group Cuts Price of Deal for Rival CWT

21 mar 2025, 16:31 UTC

Principales Movimientos del Mercado

Boeing Shares Rise After Winning $20 Billion Air Force Contract

21 mar 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 mar 2025, 22:15 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms: Unit Will Provide $185M to Rhodium on Deal Close >RIOT

21 mar 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms: Motion Filed to Approve Settlement in Rhodium's Bankruptcy Case

21 mar 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms Enters Non-Binding Term Sheet to Buy Certain Assets of Rhodium Encore >RIOT

21 mar 2025, 22:03 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- 4th Update

21 mar 2025, 21:05 UTC

Principales Noticias

The Score: Nvidia, Tesla, Nike and More Stocks That Defined the Week -- WSJ

21 mar 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

21 mar 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

21 mar 2025, 20:24 UTC

Principales Noticias

Major Indexes Stage Late Rally -- WSJ

21 mar 2025, 20:01 UTC

Principales Noticias

Columbia Yields to Trump in Battle Over Federal Funding -- WSJ

21 mar 2025, 19:40 UTC

Charlas de Mercado

Walmart's Beauty Marketplace Push Puts Ulta Beauty at Risk -- Market Talk

21 mar 2025, 19:29 UTC

Charlas de Mercado

Oil Futures Post Moderate Weekly Gains -- Market Talk

21 mar 2025, 19:09 UTC

Charlas de Mercado

U.S. Natural Gas Futures Grapple With $4 Level -- Market Talk

21 mar 2025, 19:02 UTC

Charlas de Mercado

Gold Eases to End Record-Setting Week -- Market Talk

21 mar 2025, 18:52 UTC

Charlas de Mercado

Telus Downgraded on Leverage, Cash Flow, Dividend Concerns -- Market Talk

21 mar 2025, 18:49 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- Third Update

21 mar 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Aggressive Discounting Of Classics Could Damage Brand -- Market Talk

21 mar 2025, 18:07 UTC

Principales Noticias

Major Indexes Swing Around the Flatline -- WSJ

21 mar 2025, 18:07 UTC

Charlas de Mercado
Ganancias

Nike's Focus On Hot New Products May Not Offset Decline In Classic Styles -- Market Talk

21 mar 2025, 17:41 UTC

Charlas de Mercado
Ganancias

Nike's Turnaround Messaging May Add Some Confusion -- Market Talk

21 mar 2025, 17:41 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- Second Update

21 mar 2025, 17:41 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

21 mar 2025, 17:17 UTC

Charlas de Mercado

U.S. Oil Rig Count Slips By One to 486 -- Market Talk

21 mar 2025, 17:06 UTC

Charlas de Mercado

Bitcoin Treads Water After Trump Address -- Market Talk

21 mar 2025, 16:54 UTC

Charlas de Mercado
Ganancias

FedEx Assumed an Industrial Ramp Up That Didn't Come -- Market Talk

21 mar 2025, 16:40 UTC

Charlas de Mercado

Mexican Inflation Likely Slowed in Early March -- Market Talk

21 mar 2025, 16:25 UTC

Principales Noticias

Dow, S&P 500 Fall -- WSJ

21 mar 2025, 16:17 UTC

Principales Noticias

NY Fed's Williams Says 'Uncertainty Is High,' Sees Slower GDP Growth -- Barrons.com

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

387.39% repunte

Estimación a 12 meses

Media 11.6 USD  387.39%

Máximo 28 USD

Mínimo 4 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.33 / 2.52Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

336 / 387 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.